Literature DB >> 17872870

Taking ACE inhibitors during early pregnancy: is it safe?

Joel G Ray1, Marian J Vermeulen, Gideon Koren.   

Abstract

QUESTION: I knew that angiotensin-converting enzyme (ACE) inhibitors were risky to use during late pregnancy because they can cause renal shutdown in the fetus. Recently I heard of a study that claimed first-trimester exposure (when many patients still are unaware of their pregnancies) can also cause major malformations. Is this proven? ANSWER: A recent study did suggest an increased risk of malformations after first-trimester exposure to ACE inhibitors among women treated for hypertension. We believe this study had serious limitations that preclude drawing any conclusions at present.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872870      PMCID: PMC2234619     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  13 in total

1.  The impact of prenatal diagnosis on neural tube defect (NTD) pregnancy versus birth incidence in British Columbia.

Authors:  Margot I Van Allen; Erin Boyle; Paul Thiessen; Deborah McFadden; Douglas Cochrane; G Keith Chambers; Sylvie Langlois; Patricia Stathers; Beverly Irwin; Elizabeth Cairns; Patrick MacLeod; Marie-France Delisle; Soo-Hong Uh
Journal:  J Appl Genet       Date:  2006       Impact factor: 3.240

Review 2.  Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy.

Authors:  R F Burrows; E A Burrows
Journal:  Aust N Z J Obstet Gynaecol       Date:  1998-08       Impact factor: 2.100

Review 3.  Management of hypertension in patients with type 2 diabetes mellitus: guidelines based on current evidence.

Authors:  N M Kaplan
Journal:  Ann Intern Med       Date:  2001-12-18       Impact factor: 25.391

4.  Maternal age and malformations in singleton births.

Authors:  L M Hollier; K J Leveno; M A Kelly; D D MCIntire; F G Cunningham
Journal:  Obstet Gynecol       Date:  2000-11       Impact factor: 7.661

5.  Influence of prenatal diagnosis and pregnancy termination of fetuses with birth defects on the perinatal mortality rate in Victoria, Australia.

Authors:  Natasha Davidson; Jane Halliday; Merilyn Riley; James King
Journal:  Paediatr Perinat Epidemiol       Date:  2005-01       Impact factor: 3.980

6.  Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S.

Authors:  Edward W Gregg; Betsy L Cadwell; Yiling J Cheng; Catherine C Cowie; Desmond E Williams; Linda Geiss; Michael M Engelgau; Frank Vinicor
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

7.  Trends in congenital malformations, 1974-1999: effect of prenatal diagnosis and elective termination.

Authors:  Allyson J Peller; Marie-Noel Westgate; Lewis B Holmes
Journal:  Obstet Gynecol       Date:  2004-11       Impact factor: 7.661

8.  Maternal obesity and infant heart defects.

Authors:  Marie I Cedergren; Bengt A J Källén
Journal:  Obes Res       Date:  2003-09

Review 9.  Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines.

Authors: 
Journal:  Diabet Med       Date:  2003-12       Impact factor: 4.359

Review 10.  Maternal obesity increases congenital malformations.

Authors:  A Prentice; G Goldberg
Journal:  Nutr Rev       Date:  1996-05       Impact factor: 7.110

View more
  4 in total

1.  Drugs in pregnancy: Implications for a cardiologist.

Authors:  Karel Rakusan
Journal:  Exp Clin Cardiol       Date:  2010

2.  Taking angiotensin-converting enzyme inhibitors during pregnancy: is it safe?

Authors:  Almundher Al-Maawali; Asnat Walfisch; Gideon Koren
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

3.  Treatment optimization of angiotensin converting enzyme inhibitors and associated factors in Ayder Comprehensive Specialized Hospital: a cross-sectional study.

Authors:  Tesfay Mehari Atey; Tsegay Teklay; Solomon Weldegebreal Asgedom; Haftay Berhane Mezgebe; Gebrehiwot Teklay; Molla Kahssay
Journal:  BMC Res Notes       Date:  2018-03-28

4.  Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice.

Authors:  Maira Soto; Nicole Delatorre; Chelsie Hurst; Kathleen E Rodgers
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.